LONDON (ShareCast) - (Sharecast News) - Data science company IXICO has signed a further change order to a current contract, increasing the total contract value to €1.3m, it announced on Thursday.
The AIM-traded firm said the original contract in Alzheimer's disease was announced on 5 July last year, and that the change order reflected an extension of the contract term from September 2020 to May 2021, and the addition of new clinical sites.

It said the latest amendment resulted in a total change in the contract value of €0.5m, or 65% above the original value of €0.8m.

The board explained that change orders often occurred as part of the normal course of multi-year contracts, as the scope of services that IXICO provided could be expanded or extended during the term of a clinical trial.

"We are delighted to announce a further extension and expansion of this project," said chief executive officer Giulio Cerroni.

"This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE